
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
ERp57 CRISPR/Cas9 KO Plasmid (m) | sc-420698 | 20 µg | $397.00 |
Pdia3 encodes ERp57 (also known as PDIA3/GRP58), an endoplasmic reticulum thiol–disulfide oxidoreductase that partners with calnexin and calreticulin to promote oxidative folding and quality control of nascent glycoproteins. ERp57 supports ER proteostasis through disulfide bond formation and is closely linked to unfolded protein response signaling, ER-associated degradation, and redox homeostasis. Beyond the ER lumen, PDIA3 has been implicated in antigen presentation via MHC class I peptide loading and in modulation of signaling pathways connected to cellular stress adaptation. Dysregulation of PDIA3/ERp57 activity is associated with conditions characterized by proteotoxic and oxidative stress, including neurodegenerative and metabolic disease models, making it relevant for mechanistic studies of ER stress and immune-related processes.
ERp57 CRISPR/Cas9 KO Plasmid (m) is a pool of plasmids designed for targeted disruption of the Pdia3 gene in mouse cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the Pdia3 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the Pdia3 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish ERp57 protein expression.
This CRISPR knockout system enables efficient generation of Pdia3-deficient cell models for investigation of ERp57 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
CRISPRs +/- HDRs
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.